GNS Healthcare Licenses REFS™ Causal Machine Learning and Simulation Platform to Alexion to Accelerate Discovery of New Treatments for Rare Diseases
CAMBRIDGE, Mass. – August 10, 2017– GNS Healthcare (GNS), a leading precision medicine company that applies causal machine learning technology to large and diverse data sets to better match drugs and other health interventions to individual patients, today announced that it has entered into a license arrangement with Alexion for the rights to operate its REFS™ […]
GNS Healthcare Announces Collaboration to Power Cancer Drug Development with REFS™ Causal Machine Learning and Simulation AI Platform
CAMBRIDGE, Mass.– June 19, 2017 – GNS Healthcare (GNS), a leading precision medicine company, today announced a collaboration with Genentech, a member of the Roche Group to leverage GNS REFS™ (Reverse Engineering and Forward Simulation) causal machine learning and simulation platform to power the development of novel cancer therapies. The GNS technology turns large and diverse […]
GNS Healthcare Uncovers Novel Targets for Triple-Negative Breast Cancer Using Causal Machine Learning and Simulation Platform REFS™
New Gene Discoveries Published by the American Association for Cancer Research CAMBRIDGE, Mass. – May 31, 2017– Leading precision medicine company GNS Healthcare (GNS), today announced the discovery of novel targets, including TRIB1, which correlates with survival, progression, and metastasis in resistant breast cancer. The study, which was conducted at University of California, San Francisco, […]
GenomeWeb Article Offers Insight on GNS-Celgene Deal and Growing Demand for Causal Modeling
GNS Healthcare and Celgene have signed a service and license arrangement that allows the biopharma firm to use GNS Healthcare’s causal machine-learning and simulation platform for applications in drug discovery, clinical development, and commercialization and market access. Read the full story here.
Outsourcing Pharma Puts Spotlight on Power of Causality, Highlights GNS-Celgene Deal Licensing REFS
Celgene has made a second investment in a machine learning and simulation platform for applications across drug discovery, clinical development, and commercialization. Read the full story here.
Discoveries by GNS Healthcare Causal Machine Learning and Simulation Platform, REFS, Reveal Mechanisms Driving Key Clinical Outcomes in Multiple Myeloma
Ongoing Collaboration Leveraging the Multiple Myeloma Research Foundation CoMMpass Study Reveals Drivers of High-Risk Disease and of Durable Response CAMBRIDGE, Mass. – December 6, 2016 – GNS Healthcare (GNS), a leading precision medicine company that applies causal machine learning technology to massive and diverse data streams to better match drugs and other health interventions to individual […]
Xconomy Features Celgene-GNS REFS License, Investment Deal
Celgene has made a second investment in GNS Healthcare and is tapping into the firm’s data analytics software to boost Celgene’s drug discovery and development efforts. Read the full story here.
Celgene Enters Into Service and License Arrangement for GNS Healthcare’s Causal Machine Learning Platform to Accelerate Value-Based and Precision Medicine Development
CAMBRIDGE, Mass. – November 29, 2016 – GNS Healthcare (GNS), a leading precision medicine company that applies causal machine learning technology to massive and diverse data streams to better match drugs and other health interventions to individual patients, today announced that Celgene Corporation has entered into a service and license arrangement for the rights to […]
GNS REFS™ Causal Machine Learning Platform Featured in GEN (Genetic Engineering & Biotechnology News)
GNS Healthcare’s causal machine learning platform REFS (Reverse Engineering , Forward Simulation) turns healthcare data into actionable insights to guide precision medicine and scientific discovery. “We reverse engineer causal models from healthcare data,” explains Diane Wuest, Ph.D., associate director, precision medicine initiatives, GNS Healthcare. “Once these models are built, they can be forward simulated and queried […]
Wall Street Journal Article Highlights Role of Consumer Data in Employee Wellness Programs
Employee wellness firms and insurers are working with companies to mine data about the prescription drugs workers use, how they shop and even whether they vote, to predict their individual health needs and recommend treatments. Read the full article here.